Conference Call with Ajanta Pharma Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Ajanta Pharma announced Q3FY26 results Revenue from operations at Rs 1,375 crore against Rs 1,146 crore; up 20%. EBITDA at Rs 382 crore against Rs 321 crore; up 19%; EBITDA at 28%. Profit after tax at Rs 274 crore against Rs 233 crore; PAT at 20%; up 18%. As per IQVIA MAT December 2025, our India branded generic performance exceeded IPM growth by 28%. The higher growth came from Volumes increase, which exceeded IPM by 47% & New launches, which exceeded IPM by 59%. Result PDF